WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017205790) COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/205790 International Application No.: PCT/US2017/034759
Publication Date: 30.11.2017 International Filing Date: 26.05.2017
IPC:
A61K 9/20 (2006.01) ,A61K 9/28 (2006.01) ,A61K 36/75 (2006.01) ,A61K 38/43 (2006.01) ,A61K 38/48 (2006.01) ,A61K 47/32 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)
75
Rutaceae (Rue family)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
32
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
Applicants: RAISZADEH, Michelle Monier[US/US]; US
Inventors: RAISZADEH, Michelle Monier; US
Agent: BRADY, Joshua Bryson; US
Priority Data:
62/342,30427.05.2016US
Title (EN) COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION
(FR) COMPOSITIONS ET PROCÉDÉS DE DISSOLUTION DE THROMBOEMBOLIE
Abstract:
(EN) Disclosed herein are novel thrombolytic formula for safe and effective treatment of blood clots. In clinical trials, cats of various breeds and ages presented partial or full paralysis of one or more limbs, due to arterial thromboembolism (ATE). Average treatment ranged from 3 days to 2 weeks, depending on the clot size and time elapsed since clot was dislodged from the subject's heart. These are significant findings considering the lack of treatment options available in veterinary medicine for cats with HCM and ATE. Veterinarians often euthanize cats presenting ATE, as no safe and effective thrombolytic agent is currently available for veterinary use. Previous thrombolytics were shown to have an average mortality rate of 60% due to reperfusion injury and hemorrhaging. The disclosed formula, on the other hand, overcomes these shortcomings.
(FR) La présente invention concerne une nouvelle formule thrombolytique pour le traitement sûr et efficace de caillots sanguins. Dans des essais cliniques, des chats de races et d’âges différents ont présenté une paralysie partielle ou totale d'un ou plusieurs membres, due à une thromboembolie artérielle (TEA). Le traitement moyen est compris entre 3 jours et 2 semaines, en fonction de la taille du caillot et du temps écoulé depuis que le caillot a été délogé du cœur du sujet. Ce sont des résultats significatifs compte tenu du manque d'options de traitement disponibles en médecine vétérinaire pour des chats avec CMH et TEA. Les vétérinaires euthanasient fréquemment des chats présentant une TEA, étant donné qu'aucun agent thrombolytique sûr et efficace n'est actuellement disponible pour usage vétérinaire. Il a été démontré que les thrombolytiques précédents présentent un taux de mortalité moyen de 60 % en raison d'une lésion de reperfusion et d'une hémorragie. La formule décrite, d'autre part, surmonte ces inconvénients.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)